Predict your next investment

Investment Bank
witruthcapital.com

See what CB Insights has to offer

Investments

1

About Witruth Capital

Witruth Capital (智诚资本) is a financial service firm focusing on the Chinese primary capital market and investment banking business. With subsidiaries in investment banking & financial advisory, private equity investment, and financial technology, the company has a fundamental focus on enterprises in TMT and biopharmaceutical divisions.

Witruth Capital Headquarter Location

Room No. 2803, Building No. 10, West Part, Jianwai Soho No.4 Chaowai Avenue, Chaoyang District

Beijing, Beijing,

China

+86) 010 5365 3288

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Witruth Capital Investments

1 Investments

Witruth Capital has made 1 investments. Their latest investment was in Innovative Cellular Therapeutics as part of their Series B on April 4, 2018.

CBI Logo

Witruth Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/24/2018

Series B

Innovative Cellular Therapeutics

$28.45M

Yes

5

Date

4/24/2018

Round

Series B

Company

Innovative Cellular Therapeutics

Amount

$28.45M

New?

Yes

Co-Investors

Sources

5

Witruth Capital Team

1 Team Member

Witruth Capital has 1 team member, including current Founding Partner, Feng Lu.

Name

Work History

Title

Status

Feng Lu

Founding Partner

Current

Name

Feng Lu

Work History

Title

Founding Partner

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.